208 related articles for article (PubMed ID: 35857834)
21. Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.
Coni S; Mancuso AB; Di Magno L; Sdruscia G; Manni S; Serrao SM; Rotili D; Spiombi E; Bufalieri F; Petroni M; Kusio-Kobialka M; De Smaele E; Ferretti E; Capalbo C; Mai A; Niewiadomski P; Screpanti I; Di Marcotullio L; Canettieri G
Sci Rep; 2017 Mar; 7():44079. PubMed ID: 28276480
[TBL] [Abstract][Full Text] [Related]
22. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
23. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth.
Hatton BA; Knoepfler PS; Kenney AM; Rowitch DH; de Alborán IM; Olson JM; Eisenman RN
Cancer Res; 2006 Sep; 66(17):8655-61. PubMed ID: 16951180
[TBL] [Abstract][Full Text] [Related]
24. A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog-Dependent Tumor Growth.
Yang F; Rodriguez-Blanco J; Long J; Swiderska-Syn M; Wynn DT; Li B; Shen C; Nayak A; Ban Y; Sun X; Suter RK; McCrea HJ; Capobianco AJ; Ayad NG; Robbins DJ
Mol Cancer Res; 2022 Nov; 20(11):1598-1610. PubMed ID: 35925047
[TBL] [Abstract][Full Text] [Related]
25. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
[TBL] [Abstract][Full Text] [Related]
27. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
Kieran MW
Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
[TBL] [Abstract][Full Text] [Related]
28. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
Northcott PA; Fernandez-L A; Hagan JP; Ellison DW; Grajkowska W; Gillespie Y; Grundy R; Van Meter T; Rutka JT; Croce CM; Kenney AM; Taylor MD
Cancer Res; 2009 Apr; 69(8):3249-55. PubMed ID: 19351822
[TBL] [Abstract][Full Text] [Related]
29. STAT3 is required for Smo-dependent signaling and mediates Smo-targeted treatment resistance and tumorigenesis in Shh medulloblastoma.
Yuan L; Zhang H; Liu J; Malhotra A; Dey A; Yu B; Jella KK; McSwain LF; Schniederjan MJ; MacDonald TJ
Mol Oncol; 2022 Feb; 16(4):1009-1025. PubMed ID: 34482626
[TBL] [Abstract][Full Text] [Related]
30. Scutellariabarbata D. Don extraction selectively targets stemness-prone NSCLC cells by attenuating SOX2/SMO/GLI1 network loop.
Chen WW; Gong KK; Yang LJ; Dai JJ; Zhang Q; Wang F; Li XL; Xi SC; Du J
J Ethnopharmacol; 2021 Jan; 265():113295. PubMed ID: 32841701
[TBL] [Abstract][Full Text] [Related]
31. Pyrvinium attenuates Hedgehog signaling downstream of smoothened.
Li B; Fei DL; Flaveny CA; Dahmane N; Baubet V; Wang Z; Bai F; Pei XH; Rodriguez-Blanco J; Hang B; Orton D; Han L; Wang B; Capobianco AJ; Lee E; Robbins DJ
Cancer Res; 2014 Sep; 74(17):4811-21. PubMed ID: 24994715
[TBL] [Abstract][Full Text] [Related]
32. β-Catenin-Gli1 interaction regulates proliferation and tumor growth in medulloblastoma.
Zinke J; Schneider FT; Harter PN; Thom S; Ziegler N; Toftgård R; Plate KH; Liebner S
Mol Cancer; 2015 Feb; 14(1):17. PubMed ID: 25645196
[TBL] [Abstract][Full Text] [Related]
33. Astrocytes Promote Medulloblastoma Progression through Hedgehog Secretion.
Liu Y; Yuelling LW; Wang Y; Du F; Gordon RE; O'Brien JA; Ng JMY; Robins S; Lee EH; Liu H; Curran T; Yang ZJ
Cancer Res; 2017 Dec; 77(23):6692-6703. PubMed ID: 28986380
[TBL] [Abstract][Full Text] [Related]
34. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
Heil C
Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
[TBL] [Abstract][Full Text] [Related]
35. The stem cell-associated transcription co-factor, ZNF521, interacts with GLI1 and GLI2 and enhances the activity of the Sonic hedgehog pathway.
Scicchitano S; Giordano M; Lucchino V; Montalcini Y; Chiarella E; Aloisio A; Codispoti B; Zoppoli P; Melocchi V; Bianchi F; De Smaele E; Mesuraca M; Morrone G; Bond HM
Cell Death Dis; 2019 Sep; 10(10):715. PubMed ID: 31558698
[TBL] [Abstract][Full Text] [Related]
36. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
37. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
38. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
[TBL] [Abstract][Full Text] [Related]
39. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
[TBL] [Abstract][Full Text] [Related]
40. SALL4 is a CRL3
Lospinoso Severini L; Loricchio E; Navacci S; Basili I; Alfonsi R; Bernardi F; Moretti M; Conenna M; Cucinotta A; Coni S; Petroni M; De Smaele E; Giannini G; Maroder M; Canettieri G; Mastronuzzi A; Guardavaccaro D; Ayrault O; Infante P; Bufalieri F; Di Marcotullio L
Cell Death Differ; 2024 Feb; 31(2):170-187. PubMed ID: 38062245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
